Dermed Centrum Medyczne Sp. z o.o. — Clinical Trial Site

47 Registered trials

16 Currently recruiting

Organisation

Dermed Centrum Medyczne Sp. z o.o.

Location

Lodz, Poland

Identifier

ORG-100041258

Address

Ul. Piotrkowska 48, 90-265, Poland

Departments

"DERMED" Centrum Medyczne Sp. z o.o.
„DERMED” Centrum Medyczne Sp. zo.o.
/
#40625; Clinical Trials Department
#40625; Dermatology
#40625: DERMED Centrum Medyczne Sp. z o. o.
#45004:Niepubliczny Zaklad Opieki Zdrowotnej "DERMED" Centrum Medyczne
40625: Clinical Trials Department
40625: Dermatology
Dermatology
Dermed Centrum Medyczne
DERMED Centrum Medyczne Sp. z o.o.
DERMED Centrum Medyczne Sp. zo.o.
N/A
N/A. Private institution
NA
Niepubliczny Zakład Opieki Zdrowotnej "DERMED" Centrum Medyczne
not applicable

Clinical trials at this site (47)

Search interface

Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting

2024-520337-80-00 Palmoplantar Pustulosis 5 2026-01-07
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Ato… Recruiting

2022-501478-21-00 Atopic Dermatitis Eczema 5 2024-03-15
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
A Phase 3 Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less… Recruiting

2025-522567-15-00 Plaque Psoriasis 5 2026-04-28
A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting

2025-522578-35-00 Atopic Dermatitis 4 2026-03-30
A Study of KT-621 Administered Orally to Participants with Moderate to Severe Atopic Dermatitis (BROADEN2) Recruiting

2025-522370-36-00 Moderate to Severe Atopic Dermatitis 4 2026-02-02
Brivekimig for the treatment of moderate to severe hidradenitis suppurativa Recruiting

2025-522333-61-00 Hidradenitis suppurativa 4 2026-01-23
A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder… Recruiting

2023-506296-97-00 Moderate to Severe Plaque Psoriasis 5 2025-10-28
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
A study to learn how the study drug bimekizumab works and how safe it is in treating moderate to severe hidradenitis suppurativa in children… Recruiting

2023-505323-31-00 Hidradenitis Suppurativa 5 2025-10-09
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis Recruiting

2024-517284-23-00 Active Psoriatic Arthritis 5 2025-04-23
A study to learn how bimekizumab works in children and teenagers with moderate to severe plaque psoriasis Recruiting

2023-503859-10-00 Moderate to Severe Plaque Psoriasis 5 2024-08-12
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoria… Recruiting

2022-500408-22-00 Plaque Psoriasis 5 2022-09-14
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended

2024-510730-40-00 Hidradenitis Suppurativa 5 2024-12-12
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510339-12-00 acne vulgaris 5 2024-11-11
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
A study to learn how bimekizumab works in people with moderate to severe plaque psoriasis. Ended

2023-506333-29-00 Moderate to Severe Plaque Psoriasis 11 2024-10-01
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended

2023-506011-18-00 Vitiligo 5 2024-04-17